At a glance
- Originator Eisai Co Ltd
- Developer Schering-Plough
- Class Anti-ischaemics; Antiplatelets; Heart failure therapies
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris; Heart failure; Pulmonary hypertension; Thrombosis
Most Recent Events
- 10 Nov 1997 Discontinued-Preclinical for Thrombosis in USA (Unknown route)
- 06 Jun 1997 Preclinical development for Thrombosis in USA (Unknown route)
- 05 Jul 1996 Discontinued-II for Angina pectoris in Japan (PO)